𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The type II decoy receptor of IL-1 inhibits murine collagen-induced arthritis

✍ Scribed by Natacha Bessis; Laurence Guéry; Alberto Mantovani; Annunciata Vecchi; John E. Sims; Didier Fradelizi; Marie-Christophe Boissier


Publisher
John Wiley and Sons
Year
2000
Tongue
English
Weight
129 KB
Volume
30
Category
Article
ISSN
0014-2980

No coin nor oath required. For personal study only.

✦ Synopsis


IL-1 is a key cytokine involved in the inflammatory response. The type II receptor of IL-1 (IL-1RII) acts as a decoy receptor, binding and inhibiting the effect of IL-1. This study was undertaken to establish whether IL-1RII can ameliorate collagen-induced arthritis, a model of inflammatory arthritis in mice. We used human keratinocytes transfected with the human (h)IL-1RII gene as a source of hIL-1RII protein. We showed that these cells expressed both the membrane and soluble form of receptor. In vitro, IL-1-stimulated murine macrophage cells showed a decreased expression of TNF- § in the presence of hIL-1RII. We engrafted the hIL-1RII-transfected cells in the back of mice developing collagen-induced arthritis. We found that clinical and histological parameters of arthritis were significantly decreased in mice treated with cells producing hIL-1RII. In addition, hIL-1RII administration was able to reduce the expression of mRNA for IL-6 and myeloperoxidase in the joints of treated animals. These data show that hIL-1RII anti-inflammatory properties in the model of collageninduced arthritis in mice and could have a regulatory role in rheumatoid arthritis.


📜 SIMILAR VOLUMES


Anti-IL-12 and anti-TNF antibodies syner
✍ Debra M. Butler; Anne-Marie Malfait; Ravinder N. Maini; Fionula M. Brennan; Marc 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 128 KB 👁 2 views

The co-ordinate role of the Th1 cytokine IL-12 and the proinflammatory cytokine TNF in arthritis was explored using the DBA/1 mouse model, collagen-induced arthritis (CIA). In this study, mice with established arthritis were treated with anti-IL-12 and/or anti-TNF antibodies for 10 days from the ons